Skye Bioscience, Inc.
OTC:SKYE
1.55 (USD) • At close November 27, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Skye Bioscience, Inc. |
Symbool | SKYE |
Munteenheid | USD |
Prijs | 1.74 |
Beurswaarde | 1,690,497,028 |
Dividendpercentage | 0% |
52-weken bereik | 0.007 - 10 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Punit S. Dhillon B.A., BA |
Website | https://skyebioscience.com |
An error occurred while fetching data.
Over Skye Bioscience, Inc.
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)